Literature DB >> 2522103

Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.

E M Carvalho1, O Bacellar, A Barral, R Badaro, W D Johnson.   

Abstract

Visceral leishmaniasis is associated with an antigen-specific immunosuppression during the acute disease. Patients become responsive to Leishmania antigen in both in vivo and in vitro assays after successful antimony therapy. The cell type involved in the suppression of lymphocyte reactivity to Leishmania antigen was studied by selective depletion of mononuclear cell (MNC) populations and in co-cultivation experiments. Adherent cells were depleted on plastic and by passage on nylon wool columns. High-avidity Fc+ cells were depleted by adherence to BSA-anti-BSA complexes and OKT4+ and OKT8+ cells were depleted by treatment with monoclonal antibody (anti-OKT4+ and OKT8+) and complement. Depletion of MNC preparations of adherent cells, high-avidity Fc+ cells, OKT4+ cells and OKT8+ cells failed to restore the lymphocyte reactivity to Leishmania antigen. Antimony therapy was associated with restoration of the proliferative responses of unseparated MNC (before treatment 460 +/- 76 cpm and after treatment 4,293 +/- 1,442 cpm). Co-culture of frozen cells obtained before chemotherapy with autologous MNC obtained after treatment reduced the response of posttreatment cells to Leishmania antigen by 80%. We conclude that the antigenic specific suppression of lymphocyte proliferation in visceral leishmaniasis is cell mediated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522103      PMCID: PMC303759          DOI: 10.1172/JCI113969

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Immunity in kala-azar.

Authors:  P E MANSON-BAHR
Journal:  Trans R Soc Trop Med Hyg       Date:  1961-11       Impact factor: 2.184

2.  Conditions required for Fc-dependent immune complex enhancement of antigen-specific lymphocyte blastogenesis.

Authors:  E M Carvalho; J S Davis; D A Horwitz
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

3.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

4.  Impaired cell-mediated immunity in patients with kala-azar.

Authors:  L Hepner Levy; E Mendes
Journal:  Allergol Immunopathol (Madr)       Date:  1981 Mar-Apr       Impact factor: 1.667

5.  Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  J P Haldar; S Ghose; K C Saha; A C Ghose
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

6.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

7.  Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species.

Authors:  R Badaró; S G Reed; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  1983-05       Impact factor: 2.345

8.  Cryopreservation of human lymphocytes for sequential testing of immune competence.

Authors:  S A Birkeland
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

Authors:  E M Carvalho; R Badaró; S G Reed; T C Jones; W D Johnson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

10.  Monocyte suppression of antigen-specific lymphocyte responses in diffuse cutaneous leishmaniasis patients from the Dominican Republic.

Authors:  E A Petersen; F A Neva; A Barral; R Correa-Coronas; H Bogaert-Diaz; D Martinez; F E Ward
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

View more
  43 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Authors:  P C Melby; G B Ogden; H A Flores; W Zhao; C Geldmacher; N M Biediger; S K Ahuja; J Uranga; M Melendez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.

Authors:  Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

4.  Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.

Authors:  R Badaró; C Nascimento; J S Carvalho; F Badaró; D Russo; J L Ho; S G Reed; W D Johnson; T C Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

5.  Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.

Authors:  Tejinder Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  J Parasit Dis       Date:  2012-09-06

Review 6.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

7.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

8.  Visceral leishmaniasis (kala-azar) after a visit to the Mediterranean region.

Authors:  J Rudi; P Racz; M Hörner; B Kommerell
Journal:  Clin Investig       Date:  1993-08

Review 9.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

10.  Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus.

Authors:  J Braun; J Sieper; K L Schulte; E Thiel; K Janitschke
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.